DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 170 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 0.61 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $191,436 | -8.6% | 15,050 | +1.2% | 0.00% | – |
| Q2 2023 | $209,370 | -18.5% | 14,870 | -10.5% | 0.00% | -100.0% |
| Q1 2023 | $256,779 | -5.7% | 16,620 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $272,402 | -32.1% | 16,620 | -23.4% | 0.00% | 0.0% |
| Q3 2022 | $401,000 | +40.7% | 21,700 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $285,000 | +41.8% | 21,700 | +0.0% | 0.00% | – |
| Q1 2022 | $201,000 | -5.2% | 21,690 | 0.0% | 0.00% | – |
| Q4 2021 | $212,000 | -71.2% | 21,690 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $737,000 | -6.4% | 21,690 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $787,000 | +8.3% | 21,510 | +32.6% | 0.00% | 0.0% |
| Q1 2021 | $727,000 | -19.1% | 16,219 | +2.9% | 0.00% | -50.0% |
| Q4 2020 | $899,000 | +7.8% | 15,759 | -3.0% | 0.00% | 0.0% |
| Q3 2020 | $834,000 | +2.3% | 16,249 | +19.0% | 0.00% | 0.0% |
| Q2 2020 | $815,000 | +206.4% | 13,649 | +111.0% | 0.00% | +100.0% |
| Q1 2020 | $266,000 | -32.3% | 6,468 | +2.4% | 0.00% | 0.0% |
| Q4 2019 | $393,000 | – | 6,318 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
| SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
| Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
| Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
| Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
| Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
| Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
| SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
| Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
| Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |